Sydney, Australia – Virtus Health (“Virtus”, ASX: VRT), Australia’s largest IVF provider,
wishes to advise shareholders of trading activity in the first half of FY17 and the
potential impact for the financial year ending 30 June 2017.
As reported in our update dated 9 November 2016 we are experiencing weak IVF
cycle volumes. Medicare data released on 25 January 2017 confirmed that activity
in the Australian market in the second quarter continued to fall below prior year
levels with fresh cycle activity reported by Medicare in H1FY17 in Virtus state markets
falling by 6.0% compared to the prior year comparative period. Virtus fresh cycle
activity in Australia in this half has decreased by 7.2% on a like for like basis.
MVF Price at posting:
$1.68 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)